Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

120 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Outcomes of patients with intermediate-risk or poor-risk metastatic renal cell carcinoma who received their first cycle of nivolumab and ipilimumab in the hospital because of symptomatic disease: The MD Anderson Cancer Center experience.
Alhalabi O, Hasanov E, Wilson NR, Araujo J, Wang J, Campbell MT, Goswami S, Shah AY, Gao J, Msaouel P, Tannir NM. Alhalabi O, et al. Among authors: wilson nr. Int J Cancer. 2021 Jul 15;149(2):387-393. doi: 10.1002/ijc.33560. Epub 2021 Mar 24. Int J Cancer. 2021. PMID: 33739450 Free article.
Validation of Prognostic Scores in Patients With Metastatic Urothelial Cancer Enrolling in Phase I Targeted Therapy or Next Generation Immunotherapy Trials.
Alhalabi O, Hahn AW, Msaouel P, Meric-Bernstam F, Wilson N, Naing A, Piha-Paul S, Janku F, Pant S, Yap TA, Hong DS, Fu S, Karp D, Beltran K, Campbell E, Le H, Campbell MT, Shah A, Tannir NM, Siefker-Radtke A, Gao J, Roszik J, Subbiah V. Alhalabi O, et al. Clin Genitourin Cancer. 2022 Feb;20(1):e16-e24. doi: 10.1016/j.clgc.2021.07.004. Epub 2021 Jul 12. Clin Genitourin Cancer. 2022. PMID: 34362693
Multimodal kidney-preserving approach in localised and locally advanced high-risk upper tract urothelial carcinoma.
Alhalabi O, Campbell MT, Xiao L, Adriazola AC, Wilson NR, Siefker-Radtke AO, Corn PG, Zurita A, Jonasch E, Gao J, Adibi M, Kamat AM, Navai N, Pisters LL, Dinney C, Matin SF, Shah AY. Alhalabi O, et al. Among authors: wilson nr. BJUI Compass. 2021 Oct 11;3(1):37-44. doi: 10.1002/bco2.113. eCollection 2022 Jan. BJUI Compass. 2021. PMID: 35475152 Free PMC article.
Comparative Effectiveness Analysis of Treatment Strategies for Surgically Resectable Neuroendocrine Carcinoma of the Urinary Tract.
Alhalabi O, Wilson N, Xiao L, Lin Y, Khandelwal J, Moussa MJ, Msaouel P, Navai N, Gao J, Kamat AM, Pilie P, Shah AY, Goswami S, Matin S, Kovitz C, Holla V, Guo C, Czerniak B, Logothetis C, Corn PG, Dinney CPN, Campbell MT, Hansel DE, Tannir NM, Siefker-Radtke AO. Alhalabi O, et al. Eur Urol Oncol. 2023 Dec;6(6):611-620. doi: 10.1016/j.euo.2023.09.004. Epub 2023 Oct 11. Eur Urol Oncol. 2023. PMID: 37833193
Characteristics and outcomes of patients with blastic plasmacytoid dendritic cell neoplasm treated with frontline HCVAD.
Pemmaraju N, Wilson NR, Garcia-Manero G, Sasaki K, Khoury JD, Jain N, Borthakur G, Ravandi F, Daver N, Kadia T, DiNardo C, Jabbour E, Pierce S, Qazilbash M, Konopleva M, Kantarjian H. Pemmaraju N, et al. Among authors: wilson nr. Blood Adv. 2022 May 24;6(10):3027-3035. doi: 10.1182/bloodadvances.2021006645. Blood Adv. 2022. PMID: 35061885 Free PMC article.
120 results